Kerstin Trunzer

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert et al. · The Lancet Oncology · 2014 · 969 citations · Full text

Medicine, Melanoma, Immunology +9

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

Kerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter et al. · Journal of Clinical Oncology · 2013 · 363 citations · Full text

Medicine, Receptor Tyrosine Kinase, -Mutant Melanoma +14

Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2011 · 276 citations · Full text

Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

Mario E. Lacouture, Madeleine Duvic, Axel Hauschild et al. · The Oncologist · 2013 · 213 citations · Full text